MA29735B1 - Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine - Google Patents
Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecineInfo
- Publication number
- MA29735B1 MA29735B1 MA30631A MA30631A MA29735B1 MA 29735 B1 MA29735 B1 MA 29735B1 MA 30631 A MA30631 A MA 30631A MA 30631 A MA30631 A MA 30631A MA 29735 B1 MA29735 B1 MA 29735B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- tertbutoxyiminomethylcamptothecin
- composition containing
- microparticle composition
- topoisomerase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CETTE INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES DE MICROPARTICULES DANS LESQUELLES LE PRINCIPE ACTIF EST UN INHIBITEUR DE LA TOPOISOMÉRASE 1, PLUS PARTICULIÈREMENT, LA 7-TERT-BUTOXYIMINOMETHYLCAMPTOTHÉCINE, PERMETTANT DE TRAITER ET DE PRÉVENIR DES MALADIES PROLIFÉRANTES PARMI LESQUELLES LE CANCER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70713905P | 2005-08-10 | 2005-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29735B1 true MA29735B1 (fr) | 2008-09-01 |
Family
ID=37056484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30631A MA29735B1 (fr) | 2005-08-10 | 2008-02-08 | Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1915132A1 (fr) |
JP (1) | JP2009504616A (fr) |
KR (1) | KR20080034989A (fr) |
CN (1) | CN101287448A (fr) |
AR (1) | AR055602A1 (fr) |
AU (1) | AU2006277879A1 (fr) |
BR (1) | BRPI0614757A2 (fr) |
CA (1) | CA2618084A1 (fr) |
EC (1) | ECSP088166A (fr) |
GT (1) | GT200600364A (fr) |
IL (1) | IL189076A0 (fr) |
MA (1) | MA29735B1 (fr) |
MX (1) | MX2008001965A (fr) |
NO (1) | NO20081213L (fr) |
PE (1) | PE20070232A1 (fr) |
RU (1) | RU2008108885A (fr) |
TN (1) | TNSN08062A1 (fr) |
TW (1) | TW200800195A (fr) |
WO (1) | WO2007017514A1 (fr) |
ZA (1) | ZA200800726B (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
IT1306129B1 (it) * | 1999-04-13 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti |
EP1269994A3 (fr) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament |
GT200500310A (es) * | 2004-11-19 | 2006-06-19 | Compuestos organicos |
-
2006
- 2006-08-08 JP JP2008525580A patent/JP2009504616A/ja active Pending
- 2006-08-08 CA CA002618084A patent/CA2618084A1/fr not_active Abandoned
- 2006-08-08 KR KR1020087005632A patent/KR20080034989A/ko not_active Application Discontinuation
- 2006-08-08 WO PCT/EP2006/065160 patent/WO2007017514A1/fr active Application Filing
- 2006-08-08 AU AU2006277879A patent/AU2006277879A1/en not_active Abandoned
- 2006-08-08 BR BRPI0614757-7A patent/BRPI0614757A2/pt not_active IP Right Cessation
- 2006-08-08 AR ARP060103450A patent/AR055602A1/es not_active Application Discontinuation
- 2006-08-08 RU RU2008108885/15A patent/RU2008108885A/ru not_active Application Discontinuation
- 2006-08-08 PE PE2006000965A patent/PE20070232A1/es not_active Application Discontinuation
- 2006-08-08 TW TW095129044A patent/TW200800195A/zh unknown
- 2006-08-08 MX MX2008001965A patent/MX2008001965A/es not_active Application Discontinuation
- 2006-08-08 CN CNA200680037599XA patent/CN101287448A/zh active Pending
- 2006-08-08 EP EP06792739A patent/EP1915132A1/fr not_active Withdrawn
- 2006-08-08 GT GT200600364A patent/GT200600364A/es unknown
-
2008
- 2008-01-24 ZA ZA200800726A patent/ZA200800726B/xx unknown
- 2008-01-28 IL IL189076A patent/IL189076A0/en unknown
- 2008-02-08 MA MA30631A patent/MA29735B1/fr unknown
- 2008-02-08 TN TNP2008000062A patent/TNSN08062A1/en unknown
- 2008-02-08 EC EC2008008166A patent/ECSP088166A/es unknown
- 2008-03-07 NO NO20081213A patent/NO20081213L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TNSN08062A1 (en) | 2009-07-14 |
EP1915132A1 (fr) | 2008-04-30 |
JP2009504616A (ja) | 2009-02-05 |
AR055602A1 (es) | 2007-08-29 |
CN101287448A (zh) | 2008-10-15 |
MX2008001965A (es) | 2008-03-26 |
BRPI0614757A2 (pt) | 2011-04-12 |
WO2007017514A1 (fr) | 2007-02-15 |
ZA200800726B (en) | 2009-08-26 |
AU2006277879A1 (en) | 2007-02-15 |
KR20080034989A (ko) | 2008-04-22 |
RU2008108885A (ru) | 2009-09-20 |
CA2618084A1 (fr) | 2007-02-15 |
NO20081213L (no) | 2008-05-13 |
IL189076A0 (en) | 2008-08-07 |
ECSP088166A (es) | 2008-03-26 |
PE20070232A1 (es) | 2007-04-09 |
TW200800195A (en) | 2008-01-01 |
GT200600364A (es) | 2007-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200600414A1 (ru) | ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ) | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
UA96115C2 (uk) | Спосіб і композиція для лікування амілоїдогенних захворювань | |
TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
MA32876B1 (fr) | Anticorps dirigés contre l'angiopoïétine 2 humaine | |
ECSP045429A (es) | Combinacion de compuestos organicos | |
GT200600028A (es) | Compuestos y composiciones como inhibidores de proteina kinasa | |
ECSP056173A (es) | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 | |
NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
WO2005117882A3 (fr) | Derives d'acide hydroxamique en tant qu'inhibiteurs de metalloproteases | |
TNSN07193A1 (en) | Pharmaceutical compositions comprising a camptothecin derivate | |
HUP0302384A2 (hu) | Sejtek bioenergia metabolizmusában szerepet játszó biokémiai vegyületeket tartalmazó készítmények és alkalmazásuk | |
NO20070580L (no) | Behandling av cancer. | |
TW200628473A (en) | Novel heterocycles | |
MA30982B1 (fr) | Combinaison | |
UY29239A1 (es) | Nuevos derivados de piridotienopirimidina | |
UY29240A1 (es) | Nuevos derivados de piridotienopirimidina | |
EA200801244A1 (ru) | Применение sdf-1 для лечения и/или профилактики неврологических заболеваний | |
ATE396986T1 (de) | Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken | |
MXPA05000765A (es) | Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos. | |
EA201201550A1 (ru) | Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз | |
MA35038B1 (fr) | Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor | |
ATE541567T1 (de) | Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten | |
WO2007017513A3 (fr) | Formulations pour 7-(t-butoxy)iminomethyl camptothecine |